MISSISSAUGA, ONTARIO–(Marketwired – March 9, 2017) – KP Tissue Inc. (KPT) (TSX:KPT) reports the Q4 and full year 2016 financial and operational results of KPT and Kruger Products L.P. (KPLP). Kruger Products is Canada’s leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, and White Swan®) and the Away-From-Home market, and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 16.1% interest in KPLP.
KPLP Q4 2016 Business and Financial Highlights
- Revenue increased by 13.0% to $339.6 million in Q4 2016 compared to Q4 2015
- Adjusted EBITDA was $42.9 million in Q4 2016 compared to $30.3 million in Q4 2015, up 41.6%
- Kruger Products continues to be the market share leader in Canada
- Declared a quarterly dividend of $0.18 per share to be paid on April 17, 2017
KPLP Full Year 2016 Business and Financial Highlights
- Revenue increased by 7.8% to $1,227.9 million in 2016 compared to $1,138.9 million in 2015
- Adjusted EBITDA was $152.5 million in 2016, up from $126.4 million in 2015, a 20.6% increase
“We are extremely pleased with our results for Fiscal 2016. The record Revenue and Adjusted EBITDA performance was primarily due to higher sales volume, improved pricing and strong contribution from TAD products” said Mario Gosselin, CEO of KP Tissue and KPLP.
“We continue to be #1 in overall tissue market share in Canada, with share gains in our market leading position in the bathroom tissue category, while remaining the uncontested market leader in the facial tissue category and holding a strong #2 position in the paper towels category. In the U.S., we continue to leverage our TAD product manufacturing capacity to take advantage of growth opportunities in the U.S. premium private label market.
“In the past two years, our capital program has increased significantly, focused on projects related to capacity growth and cost reduction with quick paybacks, highlighted by our $55 million paper machine investment in Crabtree to reduce our overall paper costs. We are starting to see the benefits of these investments in our results, and expect a positive impact from capital projects on our costs going forward,” concluded Mr. Gosselin.
Q1 2017 Outlook
For the first quarter of 2017, Adjusted EBITDA is expected to increase over Q1 2016, while being seasonally lower than the fourth quarter of 2016 due primarily to twelve fewer sales days and higher advertising expenses.
KPLP Q4 2016 Financial Results
Revenue in Q4 2016 was $339.6 million, compared to $300.6 million in Q4 2015, an increase of $39.0 million or 13.0%. The increase in revenue was primarily due to higher sales volumes and a selling price increase in Canada.
Cost of sales in Q4 2016 increased to $284.2 million, compared to $259.9 million in Q4 2015, primarily due to higher sales volumes, somewhat offset by cost reduction initiatives and the impact of capital projects. As a percentage of revenue, cost of sales were 83.7% in Q4 2016 compared to 86.5% in Q4 2015.
Selling, general and administrative (SG&A) expenses in Q4 2016 were $26.4 million, compared to $23.5 million in Q4 2015. The increase was primarily due to higher selling expenses related to higher sales volumes and higher advertising expenses. As a percentage of revenue, SG&A expenses were 7.8% in Q4 2016, consistent with Q4 2015.
Adjusted EBITDA in Q4 2016 was $42.9 million, compared to $30.3 million in Q4 2015, primarily due to higher sales volume, improved pricing and mix of products sold, and the impact of cost reduction initiatives and capital projects, partially offset by higher SG&A costs. Adjusted EBITDA attributable to the sale of TAD products was $13.8 million in Q4 2016 compared to $13.2 million in Q4 2015.
Net loss in Q4 2016 was $4.5 million, compared to $0.5 million in Q4 2015, primarily due to a change in the amortized cost of the Partnership units liability of $23.2 million, and higher depreciation and interest expense of $1.2 million and $0.7 million, respectively. These increases were partially offset by higher Adjusted EBITDA of $12.6 million, a decrease in tax expense of $4.2 million, and a gain on sale of non-financial assets of $2.5 million.
Total liquidity, representing cash and cash equivalents and availability under the credit line within covenant limitations, was $103.5 million as of December 31, 2016, compared to $90.6 million as of September 25, 2016.
KPLP 2016 Financial Results
Revenue was $1,227.9 million in Fiscal 2016, compared to $1,138.9 million in Fiscal 2015, an increase of $89.0 million or 7.8%. The increase in revenue was primarily due to additional sales volume across all regions as well as a selling price increase in Canada, and the favourable impact of foreign exchange on U.S. dollar sales.
Adjusted EBITDA was $152.5 million in Fiscal 2016, compared to $126.4 million in Fiscal 2015. The increase was primarily due to higher sales volume, improved pricing and mix of products sold, and the impact of cost reduction initiatives and capital projects. These were partially offset by higher SG&A costs and the net negative impact of foreign exchange. Adjusted EBITDA attributable to the sale of TAD products was $49.0 million in Fiscal 2016 compared to $45.3 million in Fiscal 2015.
Net income was $35.5 million in Fiscal 2016, compared to $1.5 million in Fiscal 2015. The increase in net income was primarily due to higher Adjusted EBITDA of $26.1 million, a decrease in interest expense of $14.2 million, a change in the foreign exchange gain/loss of $7.2 million, a decrease in tax expense of $3.8 million, and no pension revaluation related to past service costs compared to $3.4 million in Fiscal 2015. These decreases were partially offset by a change in the amortized cost of the Partnership units liability of $19.4 million, and higher depreciation expense of $5.9 million.
KPT Q4 2016 Financial Results
KPT incurred a net loss of $0.4 million in Q4 2016. Included in the net loss was $0.7 million representing KPT’s share of KPLP’s loss. The loss was increased by the net of depreciation expense of $1.5 million related to adjustments to carrying amounts on acquisition, partially offset by an income tax recovery of $1.8 million.
KPT 2016 Financial Results
KPT incurred a net loss of $1.7 million in 2016. Included in the net loss was $5.8 million representing KPT’s share of KPLP’s income. The income was reduced by depreciation expense of $5.9 million related to adjustments to carrying amounts on acquisition and income tax expense of $1.8 million
Dividends on Common Shares
The Board of Directors of KPT declared a quarterly dividend of $0.18 per share to be paid on April 17, 2017 to shareholders of record at the close of business on March 31, 2017.
Additional Information
For additional information please refer to Management’s Discussion and Analysis (MD&A) of KPT and KPLP for the fourth quarter and year ended December 31, 2016 available on SEDAR at www.sedar.com or our website at www.kptissueinc.com.
Fourth Quarter Results Conference Call Information
KPT will hold its fourth quarter conference call on Thursday, March 9, 2017 at 8:30 a.m. Eastern Time.
Via telephone: 1-877-223-4471 or 647-788-4922
Via the internet at: www.kptissueinc.com
Presentation material referenced during the conference call will be available at www.kptissueinc.com.
A rebroadcast of the conference call will be available until midnight, April 8, 2017 by dialing 800-585-8367 or 416-621-4642 and entering passcode 59685751.
The replay of the webcast will remain available on the website until midnight, April 8, 2017.
About KP Tissue Inc. (KPT)
KPT was created to acquire, and its business is limited to holding, a limited partnership interest in KPLP, which is accounted for as an investment on the equity basis. KPT currently holds a 16.1% interest in KPLP. For more information visit www.kptissueinc.com.
About Kruger Products L.P. (KPLP)
KPLP is Canada’s leading manufacturer of quality tissue products for household, industrial and commercial use. KPLP serves the Canadian consumer market with such well-known brands as Cashmere®, Purex®, SpongeTowels®, Scotties® and White Swan®. In the U.S., KPLP manufactures the White Cloud® brand, as well as many private label products. The Away-From-Home division manufactures and distributes high-quality, cost-effective product solutions to a wide range of commercial and public entities. KPLP has approximately 2,500 employees and operates eight production facilities in North America, including five FSC® CoC-certified plants (FSC® C104904), four of which are located in Canada and one in the U.S. For more information visit www.krugerproducts.ca.
Non-IFRS Measures
This press release uses certain non-IFRS financial measures which KPLP believes provide useful information to management of KPLP and the readers of the financial information in measuring the financial performance and financial condition of KPLP. These measures do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similarly titled measures presented by other companies. An example of such a measure is Adjusted EBITDA. Beginning with Q4 2015 in accordance with Canadian Securities Administrators Staff Notice 52-306 (Revised), we reference Adjusted EBITDA as a non-IFRS financial measure. This term replaces the previously referenced non-IFRS financial measure EBITDA. Our definition of Adjusted EBITDA is unchanged from our former definition of EBITDA. Accordingly, this change in terminology has no impact on our reported financial results for prior periods. Adjusted EBITDA is not a measurement of operating performance computed in accordance with IFRS and should not be considered as a substitute for operating income, net income or cash flows from operating activities computed in accordance with IFRS. “Adjusted EBITDA” is calculated by KPLP as net income (loss) before (i) interest expense, (ii) income taxes, (iii) depreciation, (iv) amortization, (v) impairment (gain on sale) of non-financial assets, (vi) loss (gain) on disposal of property, plant and equipment, (vii) foreign exchange loss (gain), (viii) costs related to restructuring activities, (ix) changes in the amortized cost of the Partnership units liability, and (x) one-time costs due to pension revaluations related to past service. A reconciliation of Adjusted EBITDA to the relevant reported results can be found in the MD&A of KPT and KPLP for the fourth quarter ended December 31, 2016 available on SEDAR at www.sedar.com.
Forward-Looking Statements
Certain statements in this press release about KPT’s and KPLP’s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments constitute forward-looking statements. The words “may”, “will”, “would”, “should”, “could”, “expects”, “plans”, “intends”, “trends”, “indications”, “anticipates”, “believes”, “estimates”, “predicts”, “likely” or “potential” or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. The forward-looking information is based on certain key expectations and assumptions made by KPT, including expectations and assumptions concerning the impact of the TAD Project on Adjusted EBITDA, the expectation of continued growth in sales of TAD products in the U.S., and stable interest rates. Although KPT believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information since no assurance can be given that such expectations and assumptions will prove to be correct.
The outlook provided in respect of Adjusted EBITDA for Q1 2017 is forward-looking information and is subject to the risk and uncertainties referred to below. The purpose of the outlook is to provide the reader with an indication of management’s expectations, at the date of this press release, regarding KPLP’s future financial performance. Readers are cautioned that this information may not be appropriate for other purposes.
Many factors could cause KPLP’s actual results, level of activity, performance or achievements or future events or developments (which could in turn affect the economic benefits derived from the Corporation’s economic interest in KPLP) to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the following factors, which are discussed in greater detail in the “Risk Factors – Risks Related to KPLP’s Business” section of the KPT Annual Information Form dated March 9, 2017 available on SEDAR at www.sedar.com: Kruger Inc.’s influence over KPLP; KPLP’s reliance on Kruger Inc.; consequences of an event of insolvency relating to Kruger Inc.; risks associated with the TAD Project; operational risks; Gatineau Plant land lease; significant increases in input costs; reduction in supply of fibre; increased pricing pressure and intense competition; KPLP’s inability to innovate effectively; adverse economic conditions; dependence on key retail trade customers; damage to the reputation of KPLP or KPLP’s brands; KPLP’s sales being less than anticipated; KPLP’s failure to implement its business and operating strategies; KPLP’s obligation to make regular capital expenditures; KPLP’s entering into unsuccessful acquisitions; KPLP’s dependence on key personnel; KPLP’s inability to retain its existing customers or obtain new customers; KPLP’s loss of key suppliers; KPLP’s failure to adequately protect its intellectual property rights; KPLP’s reliance on third party intellectual property licenses; adverse litigation and other claims affecting KPLP; material expenditures due to comprehensive environmental regulation affecting KPLP’s cash flow; KPLP’s pension obligations are significant and can be materially higher than predicted if KPLP Management’s underlying assumptions are incorrect; labour disputes adversely affecting KPLP’s cost structure and KPLP’s ability to run its plants; exchange rate and U.S. competitors; KPLP’s inability to service all of its indebtedness; exposure to potential consumer product liability, restrictive covenants; interest rate and refinancing risk; information technology; cyber-security; insurance; internal controls and trade related risk.
Readers should not place undue reliance on forward-looking statements made herein. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. The forward-looking information contained herein is made as of the date of press release and KPT undertakes no obligation to publicly update such forward-looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws.
| Kruger Products L.P. | |||||
| Consolidated Statement of Financial Position | |||||
| (thousands of Canadian dollars) | |||||
| December 31, 2016 | December 31, 2015 | ||||
| $ | $ | ||||
| Assets | |||||
| Current assets | |||||
| Cash and cash equivalents | 36,511 | 25,455 | |||
| Trade and other receivables | 123,095 | 108,720 | |||
| Receivables from related parties | 185 | 185 | |||
| Current portion of advances to partners | 5,465 | 2,630 | |||
| Inventories | 179,543 | 184,985 | |||
| Income tax recoverable | 423 | 772 | |||
| Prepaid expenses | 7,286 | 8,429 | |||
| 352,508 | 331,176 | ||||
| Non-current assets | |||||
| Advances to partners | – | 4,234 | |||
| Property, plant & equipment | 762,270 | 737,708 | |||
| Other long-term assets | 6,075 | 8,107 | |||
| Goodwill | 160,939 | 160,939 | |||
| Intangible assets | 15,270 | 15,853 | |||
| Deferred income taxes | 39,913 | 39,411 | |||
| Total assets | 1,336,975 | 1,297,428 | |||
| Liabilities | |||||
| Current liabilities | |||||
| Bank indebtedness | 9,007 | – | |||
| Trade and other payables | 201,477 | 180,329 | |||
| Payables to related parties | 3,606 | 3,775 | |||
| Income tax payable | 1,779 | – | |||
| Distributions payable | 10,148 | 9,871 | |||
| Current portion of provisions | 1,885 | 3,096 | |||
| Current portion of long-term debt | 8,859 | 10,183 | |||
| 236,761 | 207,254 | ||||
| Non-current liabilities | |||||
| Long-term debt | 415,379 | 425,859 | |||
| Other long-term liabilities | – | 48 | |||
| Provisions | 6,487 | 6,180 | |||
| Pensions | 92,646 | 87,164 | |||
| Post-retirement benefits | 57,162 | 57,346 | |||
| Liabilities to non-unitholders | 808,435 | 783,851 | |||
| Current portion of Partnership units liability | 8,611 | 2,630 | |||
| Long-term portion of Partnership units liability | 137,296 | 122,546 | |||
| Total Partnership units liability | 145,907 | 125,176 | |||
| Total liabilities | 954,342 | 909,027 | |||
| Equity | |||||
| Partnership units | 336,576 | 318,012 | |||
| Deficit | (42,792 | ) | (29,416 | ) | |
| Accumulated other comprehensive income | 88,849 | 99,805 | |||
| Total equity | 382,633 | 388,401 | |||
| Total equity and liabilities | 1,336,975 | 1,297,428 | |||
| Kruger Products L.P. | |||||||||
| Consolidated Statement of Comprehensive Income | |||||||||
| (thousands of Canadian dollars) | |||||||||
| 13-week | 13-week | ||||||||
| period ended | period ended | Year ended | Year ended | ||||||
| December 31, 2016 | December 31, 2015 | December 31, 2016 | December 31, 2015 | ||||||
| $ | $ | $ | $ | ||||||
| Revenue | 339,626 | 300,583 | 1,227,896 | 1,138,870 | |||||
| Expenses | |||||||||
| Cost of sales | 284,299 | 259,842 | 1,031,647 | 970,759 | |||||
| Selling, general and administrative expenses | 26,480 | 23,452 | 92,763 | 87,978 | |||||
| Gain on sale of non-financial assets | (2,544 | ) | 12 | (2,939 | ) | (1,119 | ) | ||
| Restructuring costs, net | 134 | 989 | 552 | 2,824 | |||||
| Operating income | 31,257 | 16,288 | 105,873 | 78,428 | |||||
| Interest expense | 10,673 | 10,095 | 44,000 | 58,164 | |||||
| Other expense | 23,061 | 561 | 22,754 | 11,331 | |||||
| Income (loss) before income taxes | (2,477 | ) | 5,632 | 39,119 | 8,933 | ||||
| Income taxes | 2,017 | 6,157 | 3,629 | 7,439 | |||||
| Net income (loss) for the period | (4,494 | ) | (525 | ) | 35,490 | 1,494 | |||
| Other comprehensive income (loss) | |||||||||
| Items that will not be reclassified to net income (loss): | |||||||||
| Remeasurements of pensions | 55,495 | 11,217 | (8,491 | ) | 7,094 | ||||
| Remeasurements of post-retirement benefits | 4,613 | (1,965 | ) | 94 | (2,667 | ) | |||
| Items that may be subsequently reclassified to net income (loss): | |||||||||
| Available-for-sale investment | – | 513 | (290 | ) | 207 | ||||
| Cumulative translation adjustment | 6,192 | 13,242 | (10,666 | ) | 56,135 | ||||
| Total other comprehensive income (loss) for the period | 66,300 | 23,007 | (19,353 | ) | 60,769 | ||||
| Comprehensive income for the period | 61,806 | 22,482 | 16,137 | 62,263 | |||||
| Kruger Products L.P. | |||||||||
| Consolidated Statement of Cash Flows | |||||||||
| (thousands of Canadian dollars) | |||||||||
| 13-week | 13-week | ||||||||
| period ended | period ended | Year ended | Year ended | ||||||
| December 31, 2016 | December 31, 2015 | December 31, 2016 | December 31, 2015 | ||||||
| $ | $ | $ | $ | ||||||
| Cash flows from (used in) operating activities | |||||||||
| Net income (loss) for the period | (4,494 | ) | (525 | ) | 35,490 | 1,494 | |||
| Items not affecting cash | |||||||||
| Depreciation | 13,661 | 12,189 | 47,436 | 41,643 | |||||
| Amortization | 270 | 318 | 1,146 | 881 | |||||
| Loss on sale of fixed assets | 142 | 450 | 139 | 734 | |||||
| Change in amortized cost of Partnership units liability | 22,129 | (1,010 | ) | 23,363 | 4,003 | ||||
| Gain on sale of investment | – | – | (324 | ) | – | ||||
| Foreign exchange (gain) loss | 932 | 1,578 | (285 | ) | 6,906 | ||||
| Interest expense | 10,673 | 10,095 | 44,000 | 58,164 | |||||
| Pension and post retirement benefits | 2,597 | 2,685 | 10,402 | 14,146 | |||||
| Provisions | 147 | 229 | 1,338 | 3,034 | |||||
| Income taxes | 2,017 | 6,157 | 3,629 | 7,439 | |||||
| Gain on sale of non-financial assets | (2,544 | ) | 12 | (2,939 | ) | (1,119 | ) | ||
| Total items not affecting cash | 50,024 | 32,703 | 127,905 | 135,831 | |||||
| Net change in non-cash working capital | 11,857 | (4,382 | ) | 1,386 | (24,540 | ) | |||
| Contributions to pension and post-retirement benefit plans | (4,417 | ) | (11,553 | ) | (18,335 | ) | (23,084 | ) | |
| Provisions paid | (815 | ) | (2,580 | ) | (2,267 | ) | (3,558 | ) | |
| Income tax payments | (83 | ) | (557 | ) | (1,970 | ) | (2,107 | ) | |
| Net cash from operating activities | 52,072 | 13,106 | 142,209 | 84,036 | |||||
| Cash flows from (used in) investing activities | |||||||||
| Purchases of property, plant & equipment | (22,794 | ) | (21,552 | ) | (81,460 | ) | (54,701 | ) | |
| Capitalized interest paid | (222 | ) | – | (222 | ) | – | |||
| Proceeds on sale of investment | – | – | 1,439 | – | |||||
| Government assistance received | 1,191 | – | 2,400 | – | |||||
| Purchases of software | (492 | ) | (722 | ) | (563 | ) | (2,682 | ) | |
| Proceeds on sale of property, plant and equipment | 4,860 | – | 5,399 | 736 | |||||
| Net cash used in investing activities | (17,457 | ) | (22,274 | ) | (73,007 | ) | (56,647 | ) | |
| Cash flows from (used in) financing activities | |||||||||
| Proceeds from long-term debt | 4,614 | 206,000 | 9,609 | 206,000 | |||||
| Repayment of long-term debt | (9,776 | ) | (179,976 | ) | (17,882 | ) | (184,856 | ) | |
| Payment of deferred financing fees | (34 | ) | (1,248 | ) | (745 | ) | (1,388 | ) | |
| Interest paid on long-term debt | (15,868 | ) | (22,603 | ) | (34,162 | ) | (44,978 | ) | |
| Distributions and advances paid, net | (5,979 | ) | (7,156 | ) | (22,862 | ) | (31,811 | ) | |
| Proceeds from issuing Partnership units | – | – | – | 195 | |||||
| Net cash used in financing activities | (27,043 | ) | (4,983 | ) | (66,042 | ) | (56,838 | ) | |
| Effect of exchange rate changes on cash and cash equivalents held in foreign currency | 408 | 1,059 | (1,111 | ) | 3,116 | ||||
| Increase (decrease) in cash and cash equivalents during the period | 7,980 | (13,092 | ) | 2,049 | (26,333 | ) | |||
| Cash and cash equivalents – Beginning of period | 19,524 | 38,547 | 25,455 | 51,788 | |||||
| Cash and cash equivalents – End of period | 27,504 | 25,455 | 27,504 | 25,455 | |||||
| Kruger Products L.P. | |||||||||
| Segment and Geographic Results | |||||||||
| (thousands of Canadian dollars) | |||||||||
| 13-week | 13-week | ||||||||
| period ended | period ended | Year ended | Year ended | ||||||
| December 31, 2016 | December 31, 2015 | December 31, 2016 | December 31, 2015 | ||||||
| $ | $ | $ | $ | ||||||
| Segment Information | |||||||||
| Segment Revenue | |||||||||
| Consumer | 277,543 | 240,583 | 986,881 | 897,959 | |||||
| AFH | 59,549 | 54,799 | 227,062 | 220,320 | |||||
| Other | 2,534 | 5,201 | 13,953 | 20,591 | |||||
| Total segment revenue | 339,626 | 300,583 | 1,227,896 | 1,138,870 | |||||
| Segment Adjusted EBITDA | |||||||||
| Consumer | 40,469 | 30,726 | 146,367 | 122,483 | |||||
| AFH | 2,452 | 621 | 5,217 | 5,407 | |||||
| Other | (1 | ) | (1,094 | ) | 947 | (1,505 | ) | ||
| Total segment Adjusted EBITDA | 42,920 | 30,253 | 152,531 | 126,385 | |||||
| Reconciliation to Net Income (Loss): | |||||||||
| Depreciation and amortization | 13,931 | 12,507 | 48,582 | 42,524 | |||||
| Interest expense | 10,673 | 10,095 | 44,000 | 58,164 | |||||
| Change in amortized cost of Partnership units liability | 22,129 | (1,010 | ) | 23,363 | 4,003 | ||||
| Loss on sale of fixed assets | 142 | 450 | 139 | 734 | |||||
| Pension revaluation – past service cost | – | – | – | 3,416 | |||||
| Gain on sale of non-financial assets | (2,544 | ) | 12 | (2,939 | ) | (1,119 | ) | ||
| Restructuring costs | 134 | 989 | 552 | 2,824 | |||||
| Foreign exchange (gain) loss | 932 | 1,578 | (285 | ) | 6,906 | ||||
| Income (loss) before income taxes | (2,477 | ) | 5,632 | 39,119 | 8,933 | ||||
| Income taxes | 2,017 | 6,157 | 3,629 | 7,439 | |||||
| Net income (loss) | (4,494 | ) | (525 | ) | 35,490 | 1,494 | |||
| Geographic Revenue | |||||||||
| Canada | 209,605 | 184,512 | 746,483 | 711,881 | |||||
| U.S. | 115,767 | 103,384 | 429,627 | 389,154 | |||||
| Mexico | 14,254 | 12,687 | 51,786 | 37,835 | |||||
| Total revenue | 339,626 | 300,583 | 1,227,896 | 1,138,870 | |||||
| KP Tissue Inc. | |||||
| Statement of Financial Position | |||||
| (thousands of Canadian dollars) | |||||
| December 31, 2016 | December 31, 2015 | ||||
| $ | $ | ||||
| Assets | |||||
| Current assets | |||||
| Distributions receivable | 1,636 | 1,613 | |||
| Receivable from Partnership | 426 | – | |||
| Income tax recoverable | – | 828 | |||
| 2,062 | 2,441 | ||||
| Non-current assets | |||||
| Investment in associate | 117,349 | 126,643 | |||
| Total Assets | 119,411 | 129,084 | |||
| Liabilities | |||||
| Current liabilities | |||||
| Dividend payable | 1,636 | 1,613 | |||
| Payable to Partnership | – | 108 | |||
| Current portion of advances from Partnership | 914 | 432 | |||
| Income tax payable | 884 | – | |||
| 3,434 | 2,153 | ||||
| Non-current liabilities | |||||
| Advances from Partnership | – | 709 | |||
| Deferred income taxes | 893 | 1,007 | |||
| Total liabilities | 4,327 | 3,869 | |||
| Equity | |||||
| Common shares | 13,176 | 11,577 | |||
| Contributed surplus | 144,819 | 144,819 | |||
| Deficit | (58,729 | ) | (49,291 | ) | |
| Accumulated other comprehensive income | 15,818 | 18,110 | |||
| Total equity | 115,084 | 125,215 | |||
| Total liabilities and equity | 119,411 | 129,084 | |||
| KP Tissue Inc. | |||||||||
| Statement of Comprehensive Income (Loss) | |||||||||
| (thousands of Canadian dollars, except share and per share amounts) | |||||||||
| 13-week | 13-week | ||||||||
| period ended | period ended | Year ended | Year ended | ||||||
| December 31, 2016 | December 31, 2015 | December 31, 2016 | December 31, 2015 | ||||||
| $ | $ | $ | $ | ||||||
| Equity loss | (2,225 | ) | (1,516 | ) | (124 | ) | (5,480 | ) | |
| Dilution gain (loss) | 49 | (59 | ) | 191 | 70 | ||||
| Impairment in investment in associate | – | (28,000 | ) | – | (28,000 | ) | |||
| Income (loss) before income taxes | (2,176 | ) | (29,575 | ) | 67 | (33,410 | ) | ||
| Income taxes | (1,768 | ) | (1,796 | ) | 1,789 | (2,066 | ) | ||
| Net loss for the period | (408 | ) | (27,779 | ) | (1,722 | ) | (31,344 | ) | |
| Other comprehensive income (loss) net of tax expense (recovery) | |||||||||
| Items that will not be reclassified to net loss: | |||||||||
| Remeasurements of pensions | 7,839 | 1,603 | (1,195 | ) | 1,013 | ||||
| Remeasurements of post-retirement benefits | 456 | (196 | ) | 9 | (267 | ) | |||
| Items that may be subsequently reclassified to net loss: | |||||||||
| Available-for-sale investment | – | 72 | (41 | ) | 29 | ||||
| Cumulative translation adjustment | 1,244 | 2,376 | (2,251 | ) | 10,223 | ||||
| Total other comprehensive income (loss) for the period | 9,539 | 3,855 | (3,478 | ) | 10,998 | ||||
| Comprehensive income (loss) for the period | 9,131 | (23,924 | ) | (5,200 | ) | (20,346 | ) | ||
| Basic loss per share | (0.04 | ) | (3.12 | ) | (0.19 | ) | (3.52 | ) | |
| Weighted average number of shares outstanding | 9,084,494 | 8,952,820 | 9,037,833 | 8,910,948 | |||||
| KP Tissue Inc. | |||||||||
| Statement of Cash Flows | |||||||||
| (thousands of Canadian dollars) | |||||||||
| 13-week | 13-week | ||||||||
| period ended | period ended | Year ended | Year ended | ||||||
| December 31, 2016 | December 31, 2015 | December 31, 2016 | December 31, 2015 | ||||||
| $ | $ | $ | $ | ||||||
| Cash flows from (used in) operating activities | |||||||||
| Net loss for the period | (408 | ) | (27,779 | ) | (1,722 | ) | (31,344 | ) | |
| Items not affecting cash | |||||||||
| Equity loss | 2,225 | 1,516 | 124 | 5,480 | |||||
| Dilution gain (loss) | (49 | ) | 59 | (191 | ) | (70 | ) | ||
| Impairment in investment in associate | – | 28,000 | – | 28,000 | |||||
| Income taxes | (1,768 | ) | (1,796 | ) | 1,789 | (2,066 | ) | ||
| Total items not affecting cash | 408 | 27,779 | 1,722 | 31,344 | |||||
| Tax payments | – | (307 | ) | (205 | ) | (1,712 | ) | ||
| Tax Distribution received | – | – | – | 571 | |||||
| Advances received | – | 307 | 205 | 1,141 | |||||
| Net cash from (used in) operating activities | – | – | – | – | |||||
| Cash flows from (used in) investing activites | |||||||||
| Investment in associate | – | – | – | (195 | ) | ||||
| Partnership unit distributions received | 1,180 | 1,205 | 4,908 | 5,217 | |||||
| Net cash from investing activities | 1,180 | 1,205 | 4,908 | 5,022 | |||||
| Cash flows from (used in) financing activities | |||||||||
| Issuance of common shares | – | – | – | 195 | |||||
| Dividends paid | (1,180 | ) | (1,205 | ) | (4,908 | ) | (5,217 | ) | |
| Net cash used in financing activities | (1,180 | ) | (1,205 | ) | (4,908 | ) | (5,022 | ) | |
| Increase (decrease) in cash and cash equivalents during the period | – | – | – | – | |||||
| Cash and cash equivalents – Beginning of period | – | – | – | – | |||||
| Cash and cash equivalents – End of period | – | – | – | – | |||||
Francois Paroyan
General Counsel and Corporate Secretary
KP Tissue Inc.
905.812.6936
[email protected]
INVESTORS:
Mike Baldesarra
Director of Investor Relations
KP Tissue Inc.
905.812.6962
[email protected]
